{"entity":{"id":"stephen-hunger","kind":"person","name":"Stephen P. Hunger","aka":[],"tldr":"Chaired the COG leukaemia committee through the era that pushed childhood ALL cure rates above 90%.","summary":"Stephen Hunger chaired the Children's Oncology Group acute lymphoblastic leukaemia committee from 2008 to 2016 and led the analyses documenting improved survival across successive trials, the Ph-like ALL discovery work with Charles Mullighan, and the trials that added imatinib to chemotherapy for Philadelphia-positive ALL. He co-authored the NEJM review of childhood ALL and leads oncology at CHOP.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Stephen_P._Hunger","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hunger%20SP%5BAuthor%5D%20acute%20lymphoblastic%20leukemia%20children"}],"tags":["paediatric","all","cooperative-group"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":["imatinib","blinatumomab"],"companies":[],"institutions":["chop"],"pathways":[],"terms":[],"trials":["aall1731"],"people":[],"bottlenecks":[],"keyPapers":["paper-aall1731-blinatumomab-children-nejm-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Oncology, Children's Hospital of Philadelphia; Jeffrey E. Perelman Distinguished Chair in Pediatrics","institutionId":"chop","specialisms":["Paediatric acute lymphoblastic leukaemia","Cooperative-group trials","Leukaemia genomics","Risk stratification"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hunger%20SP%5BAuthor%5D%20acute%20lymphoblastic%20leukemia%20children"}],"papers":[{"title":"Acute lymphoblastic leukemia in children","journal":"NEJM","year":2015,"doi":"10.1056/NEJMra1400972"},{"title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group","journal":"JCO","year":2012,"doi":"10.1200/JCO.2011.37.8018"},{"title":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AALL1731%20blinatumomab%20standard-risk%20B-ALL%20children%20Gupta%20NEJM%202025"}],"orcid":"0000-0002-5492-3957"},"route":"/people/stephen-hunger/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"}],"institution":[{"id":"chop","kind":"institution","name":"Children's Hospital of Philadelphia","route":"/institutions/chop/"}],"trial":[{"id":"aall1731","kind":"trial","name":"COG AALL1731","route":"/trials/aall1731/"}],"paper":[{"id":"paper-aall1731-blinatumomab-children-nejm-2025","kind":"paper","name":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","route":"/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/"}]}}